MRC/NCRI, UK.
Int J Gynecol Cancer. 2011 May;21(4):763-70. doi: 10.1097/IGC.0b013e31821b2669.
There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.
目前，人们对卵巢癌的分子途径有了更深入的了解，利用这些知识，可以测试大量新的治疗药物。这些药物的成功将取决于选择针对已知关键功能失调分子途径的药物。为了充分利用这些化合物，需要确定预后和预测生物标志物。需要开发新的评估方法，如功能成像，作为额外的生物学终点来评估这些治疗方法。一些药物已经观察到有抗肿瘤活性，需要仔细考虑在何种情况下，新的药物，如抗血管生成化合物，可以被视为标准治疗。这些领域在第四届卵巢癌共识会议上进行了讨论。
